The University of Maryland School of Medicine, located in Baltimore City, Maryland, U.S., is the medical school of the University of Maryland, Baltimore and is affiliated with the University of Maryland Medical Center and Medical System.

During the past decade, University of Maryland School of Medicine - Center for Vaccine Development - Baltimore conducted 32 clinical trials. In the 10-year time frame, 32 clinical trials started and 15 clinical trials were completed, i.e. on average, 46.9% percent of trials that started reached the finish line to date. In the past 5 years, 17 clinical trials started and 12 clinical trials were completed. i.e. 70.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Maryland School of Medicine - Center for Vaccine Development - Baltimore" #1 sponsor was "National Institute of Allergy and Infectious Diseases (NIAID)" with 35 trials, followed by "University of Maryland, Baltimore" with 15 trials sponsored, "Sanaria Inc." with 2 trials sponsored, "Intralytix, Inc." with 1 trials sponsored and "LigoCyte Pharmaceuticals, Inc." with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Maryland School of Medicine - Center for Vaccine Development - Baltimore" #1 collaborator was "PATH" with 3 trials as a collaborator, "Food and Drug Administration (FDA)" with 2 trials as a collaborator, "Medical Technology Enterprise Consortium (MTEC)" with 2 trials as a collaborator, "University of Maryland, Baltimore" with 2 trials as a collaborator and "Walter Reed Army Institute of Research (WRAIR)" with 2 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "University of Maryland School of Medicine - Center for Vaccine Development - Baltimore" are "Influenza" (12 trials), "COVID-19" (4 trials), "Malaria" (4 trials), "Plasmodium Falciparum Infection" (4 trials) and "Shigella" (4 trials). Many other conditions were trialed in "University of Maryland School of Medicine - Center for Vaccine Development - Baltimore" in a lesser frequency.

Most popular intervention types in "University of Maryland School of Medicine - Center for Vaccine Development - Baltimore" are "Biological" (45 trials), "Drug" (21 trials), "Other" (20 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (15 trials), "AS03" (4 trials), "Remdesivir" (4 trials), "Phosphate Buffered Saline (PBS) diluent" (3 trials) and "Baricitinib" (2 trials). Other intervention names were less common.

The vast majority of trials in "University of Maryland School of Medicine - Center for Vaccine Development - Baltimore" are 57 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "University of Maryland School of Medicine - Center for Vaccine Development - Baltimore". undefined are not yet recruiting, 7 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 46 completed trials in University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, 29 "Phase 1" clinical trials were conducted, 17 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 0 trials that are defined as “Not Applicable".